Retatrutide is the newest triple-agonist peptide hitting the research scene — it targets GLP-1, GIP, and glucagon receptors all at once. Early research is showing it may outperform both semaglutide and tirzepatide for metabolic studies. This is the one everyone's watching.
Product Details
98%+ purity, third-party tested
Certificate of Analysis (COA) included
Fulfilled from the USA
For laboratory research use only (RUO) — not for human consumption